Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 200409. Отображено 100.
05-01-2012 дата публикации

Dispersion composition and method for manufacturing dispersion composition

Номер: US20120003288A1
Автор: Hisahiro Mori
Принадлежит: Fujifilm Corp

The present invention provides: a dispersion composition including a poorly water-soluble polyphenol compound, an emulsifier including a sucrose fatty acid ester, and a water-soluble polymer, in which a content of a polyglycerin fatty acid ester in the composition is 0, or 0.1 or fewer times a total mass of the sucrose fatty acid ester in the composition, and a particle size of the dispersed particles including the poorly water-soluble polyphenol is 200 nm or smaller; and a method for manufacturing the dispersion composition, the method including an oil phase preparation process in which an oil phase is prepared by dissolving one or more oil phase components including the poorly water-soluble polyphenol in a good solvent for the poorly water-soluble polyphenol compound, and a mixing process in which the obtained oil phase and a phase of a poor solvent for the poorly water-soluble polyphenol compound are mixed to obtain the dispersion composition which includes the poorly water-soluble polyphenol compound and includes dispersed particles having an average volume particle size of 200 nm or smaller.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Anti-inflammatory dissolvable film

Номер: US20120003292A1
Автор: Aron J. Saffer, William Zev Levine, Zvi G. Loewy
Принадлежит: Individual

Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss

Номер: US20120003300A1
Автор: Elliot Isaacs, Toby Cobbledick
Принадлежит: Pangaea Laboratories Ltd

A composition to treat hair loss and enhance hair growth and condition. The composition comprises: i) one or more of VEGF, a VEGF biomimetic peptide, and/or a VEGFR2 receptor agonist; ii) ciclopirox olamine; and iii) a pharmaceutically acceptable carrier.

Подробнее
Номер записи: 3
05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1
Автор: Claudine Kieda, Jean-Marie Lehn, Yves Claude Nicolau
Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее
Номер записи: 4
05-01-2012 дата публикации

Formulation Comprising Bioactive Agents And Method Of Using Same

Номер: US20120004170A1
Автор: Daniel Schwartz, Susan J. Sofia, Wolfgang Friess
Принадлежит: Friedrich Alexander Univeritaet Erlangen Nuernberg FAU

Disclosed are methods of making bioactive BMP-2 microparticles and methods of using the microparticles.

Подробнее
Номер записи: 5
05-01-2012 дата публикации

N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands

Номер: US20120004214A1
Автор: Dan Peters, Daniel B. Timmermann, Eva Dam Christoffersen
Принадлежит: Neurosearch AS

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Formula (I) a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ar represents an indolyl group, which indolyl may optionally be substituted one or more times with substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkyl, hydroxy and alkoxy.

Подробнее
Номер записи: 6
05-01-2012 дата публикации

Salt of cd 80 antagonist

Номер: US20120004237A1
Автор: Richard Ian MATTHEWS
Принадлежит: MEDIGENE AG

Choline salt of the CD80 antagonist compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide.

Подробнее
Номер записи: 7
05-01-2012 дата публикации

Organic compounds

Номер: US20120004247A1
Автор: Brian Cox, Robin Alec Fairhurst, Roger John Taylor
Принадлежит: NOVARTIS AG

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

Подробнее
Номер записи: 8
05-01-2012 дата публикации

Methods of using a methylxanthine compound

Номер: US20120004248A1
Автор: Clifford S. Deutschman, Richard J. Levy
Принадлежит: Deutschman Clifford S, Levy Richard J

The invention relates to compositions and methods for treating various diseases or medical conditions by administering a methylxanthine compound. Specifically, the invention relates to compositions and methods for treating cytochrome oxidase (CcOX) mediated diseases or medical conditions by administering compositions comprising a methyl xanthine compound.

Подробнее
Номер записи: 9
05-01-2012 дата публикации

Compounds for the treatment of pathologies associated with aging and degenerative disorders

Номер: US20120004263A1
Автор: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
Принадлежит: University of Pittsburgh

The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Подробнее
Номер записи: 10
05-01-2012 дата публикации

Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia

Номер: US20120004395A1
Автор: Adriano Fontana, Christoph Kundig, Mike Recher
Принадлежит: MED DISCOVERY SA, Universitaet Zuerich

The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Подробнее
Номер записи: 11
05-01-2012 дата публикации

In vitro micro-organs, and uses related thereto

Номер: US20120004642A1
Автор: Eduardo N. Mitrani
Принадлежит: Yissum Research Development Co of Hebrew University of Jerusalem

Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the preservation of an organ microarchitecture which facilitates, for example, cell-cell and cell-matrix interactions analogous to those occurring in the source organ. The micro-organ cultures of the invention can be used in methods for delivering gene products to recipient subjects, for identifying cell proliferative and cell differentiating agents, and identification and isolation of progenitor and stem cells. In addition, the micro-organ cultures of the present invention can be used in methods for identifying inhibitors of cell proliferation, cell differentiation and viral infectivity. In other embodiments, the micro-organ cultures can be used for transplantation.

Подробнее
Номер записи: 12
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
Номер записи: 13
12-01-2012 дата публикации

Recombinant surfactant protein d compositions and methods of use thereof

Номер: US20120010126A1
Автор: Howard Clark, Kenneth Bannerman Milne Reid, Palaniyar Nadesalingam, Peter Strong
Принадлежит: Medical Research Council

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Подробнее
Номер записи: 14
12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1
Автор: Atul Varadhachary, Jose Engelmayer
Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее
Номер записи: 15
12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1
Автор: Rahul Jain, Rajesh Jain, Shudhanand Prasad, Shweta Dubey, Vijay Goel, Virendra Kumar Vinayak
Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее
Номер записи: 16
12-01-2012 дата публикации

Choline and tromethamine salt of licofelone

Номер: US20120010261A1
Автор: Hans-Günter Striegel, Stefan Laufer, Wolfgang Albrecht
Принадлежит: CAIR Biosciences GmbH

The present invention relates to the choline and tromethamine salt of Licofelone.

Подробнее
Номер записи: 17
12-01-2012 дата публикации

Avermectin compounds and treatment of dermatological disorders in humans therewith

Номер: US20120010277A1
Автор: Alexandre Kaoukhov, Cecile Cousin
Принадлежит: GALDERMA SA

Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.

Подробнее
Номер записи: 18
19-01-2012 дата публикации

Soothing cosmetic or pharmaceutical composition comprising a peptide which activates hmg-coa reductase

Номер: US20120014886A1
Автор: Claude Dal Farra, Jean-Marie Botto, Nouha Domloge
Принадлежит: ISP Investments LLC

The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R 1 -(AA) n -X 1 -Gly-Lys-X 2 -(AA) p -R 2 and sequence SEQ ID No. 1 to SEQ ID No. 10, in a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.

Подробнее
Номер записи: 19
19-01-2012 дата публикации

PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS

Номер: US20120014989A1
Автор: Andrew P. Combs, Haisheng Wang, James D. Rodgers, Richard B. Sparks
Принадлежит: Incyte Corp

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Подробнее
Номер записи: 20
19-01-2012 дата публикации

Traditional chinese medicinal ointment for treating burn, scald and infective trauma and preparative method thereof

Номер: US20120015041A1
Автор: Xinwei Sun
Принадлежит: Individual

This invention is disclosing a pure ointment of traditional Chinese medicine which was invented to treat burn or scald, and infectious trauma, and its preparation. The ointment has solved a number of problems in the treatment of burn or scald, and infectious trauma, such as the high cost of current drugs, post-treatment scar, and unfavorable therapeutic effect. The advantages of this ointment include low cost, favorable therapeutic effect, short course, and without scar after treatment. Its formula is based on the weight of every five hundred portions of following ingredients: lithospermum, 4-10 portions, beeswax, 5-20 potions, insect-white wax, 5-20 portions, and lard, 450-486 portions.

Подробнее
Номер записи: 21
19-01-2012 дата публикации

Formulations for the treatment of urushiol-induced contact dermatitis

Номер: US20120015044A1
Автор: Angela Hansen, Laszlo TREIBER
Принадлежит: Laszlos Solutions Inc

Disclosed herein are compositions comprising: a pharmaceutically acceptable oxidizing agent; a pharmaceutically acceptable base; and a pharmaceutically acceptable solvent or mixture of solvents. Also disclosed are methods of treating urushiol-induced contact dermatitis in a patient, the method comprising: identifying a patient in need thereof; and administering to the patient a composition as described herein. Further disclosed herein are devices for the treatment of urushiol-induced contact dermatitis, the device comprising: an absorbent material, contained therein a composition as described herein; and means for attaching the device to the skin of a patient in need thereof.

Подробнее
Номер записи: 22
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1
Автор: Stephen Tomlinson, V. Michael Holers
Принадлежит: MUSC Foundation for Research Development, University of Colorado

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
Номер записи: 23
19-01-2012 дата публикации

Sulfone Compounds Which Modulate The CB2 Receptor

Номер: US20120015988A1
Автор: Christopher Francis Palmer, David Smith Thomson, Doris Riether, Eugene Richard Hickey, Mark Whittaker, Monika Ermann, Patricia Amouzegh, Renee M. Zindell
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
Номер записи: 24
19-01-2012 дата публикации

Pharmaceutical composition for external use

Номер: US20120015997A1
Автор: Akira Nozawa, Hirokazu Kobayashi, Hiroyuki Fujii, Toyohiko Miki
Принадлежит: Nihon Nohyaku Co Ltd, Pola Pharma Inc

Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.

Подробнее
Номер записи: 25
19-01-2012 дата публикации

Phototherapy methods and devices comprising emissive aryl-heteroaryl compounds

Номер: US20120015998A1
Автор: Amane Mochizuki, Brett T. Harding, Jensen Cayas, Keisaku Okada, Sazzadur Rahman Khan, SHENG Li, Shijun Zheng
Принадлежит: Nitto Denko Corp

Disclosed herein are compounds represented by a formula: R 1 —Ar 1 —X—Ar 2 —Ar 3 -Het, wherein R 1 , Ar 1 , X, Ar 2 , Ar 3 , and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.

Подробнее
Номер записи: 26
19-01-2012 дата публикации

Biphenyl compound selective agonists of gamma rar receptors

Номер: US20120016031A1
Автор: Etienne Thoreau, Thibaud Biadatti
Принадлежит: Galderma Research and Development SNC

Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.

Подробнее
Номер записи: 27
19-01-2012 дата публикации

Method for Synthesizing Pirfenidone

Номер: US20120016133A1
Автор: Michael Cyr, Ramachandran Radhakrishnan, Sabine M. Pyles
Принадлежит: Intermune Inc

A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.

Подробнее
Номер записи: 28
19-01-2012 дата публикации

Enzymes and methods for producing omega-3 fatty acids

Номер: US20120016144A1
Автор: Anne Maree Mackenzie, Craig Christopher Wood, Dion Matthew Frederick Frampton, James Robertson Petrie, Peter David Nichols, Peter Maged Mansour, Pushkar Shrestha, Qing Liu, Stanley Suresh Robert, Surinder Pal Singh, Susan Irene Ellis Blackburn, Xue-Rong Ziiou
Принадлежит: Individual

The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Подробнее
Номер записи: 29
26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1
Автор: Edward K.Y. Jung, Elizabeth A. Sweeney, Eric C. Leuthardt, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Stephen L. Malaska, Wayne R. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее
Номер записи: 30
26-01-2012 дата публикации

Methods for accelerating wound healing by administration of adipokines

Номер: US20120020917A1
Автор: Inessa Solomonik, Liora Braiman-Wiksman
Принадлежит: Individual

Methods for inducing or accelerating a healing process of a damaged skill or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound.

Подробнее
Номер записи: 31
26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1
Автор: Curtis Thompson, Gregory I. Frost, Harold Michael Shepard, Xiaoming Li
Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее
Номер записи: 32
26-01-2012 дата публикации

METHODS FOR TREATING IgE-MEDIATED DISORDER

Номер: US20120020979A1
Автор: Andrea Cerutti, KANG Chen
Принадлежит: CORNELL UNIVERSITY

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Подробнее
Номер записи: 33
26-01-2012 дата публикации

Formulations and treatments for trichology

Номер: US20120020982A1
Автор: Jon Phillips
Принадлежит: Individual

A formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g: phytosterols in the range of 200 mg to 2500 mg; the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg; methylsulfonylmethane in the range of 500 mg to 2000 mg; and bovine colostrum in the range of 500 m to 2000 m.

Подробнее
Номер записи: 34
26-01-2012 дата публикации

Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof

Номер: US20120021002A1
Автор: Konstantin Ichtchenko, Philip A. Band
Принадлежит: New York University NYU

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

Подробнее
Номер записи: 35
26-01-2012 дата публикации

Corrosion current-generating metal particulates and use thereof

Номер: US20120021014A1
Автор: Brooks Story, Chunlin Yang, James E. Hauschild, Jeannette Chantalat, Jeffrey C. Geesin, Jue-Chen Liu, Julia Hwang, Michael D. Southall, Wei Kong, William R. Parrish, Ying Sun
Принадлежит: Johnson and Johnson Consumer Companies LLC

Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.

Подробнее
Номер записи: 36
26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1
Автор: Afa Kehaati Palu, Brett Justin West, Claude Jarakae Jensen, Jeffery A. Wasden, Shixin Deng
Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее
Номер записи: 37
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
Номер записи: 38
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Автор: Andreas Maderna, Dinesh Barawkar, Hassan El Abdellaoul, Jean-Michel Vernier, Varaprasad Chamakura, Zhi Hong
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
Номер записи: 39
26-01-2012 дата публикации

Heterocyclic antagonists of prostaglandin d2 receptors

Номер: US20120022119A1
Автор: Brian Andrew Stearns, Jeffrey Roger Roppe, John Howard Hutchinson, Nicholas Simon Stock, Timothy Parr
Принадлежит: Amira Pharmaceuticals Inc

Described herein are heteroaryl compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Подробнее
Номер записи: 40
26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1
Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
Номер записи: 41
26-01-2012 дата публикации

Compositions and Methods for Induced Brown Fat Differentiation

Номер: US20120022500A1
Автор: Bruce M. Spiegelman, Shingo Kajimura
Принадлежит: Dana Farber Cancer Institute Inc

The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm1β and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm1β and C/EBPβ expression and/or activity.

Подробнее
Номер записи: 42
02-02-2012 дата публикации

Transdermal pharmaceutical preparations

Номер: US20120024743A1
Автор: Endre Mikulásik, Patrik Fazekas
Принадлежит: EGIS PHARMACEUTICALS PLC

The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.

Подробнее
Номер записи: 43
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
Номер записи: 44
02-02-2012 дата публикации

Thermoreversible collagen

Номер: US20120027732A1
Автор: Sherry L. Voytik-Harbin
Принадлежит: PURDUE RESEARCH FOUNDATION

This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation.

Подробнее
Номер записи: 45
02-02-2012 дата публикации

Modified heparinase iii and methods of sequencing therewith

Номер: US20120027744A1
Автор: Dongfang Liu, Ganesh Venkataraman, Kevin Pojasek, Kristine Holley, Ram Sasisekharan, Yosuf El-Shabrawi, Zachary Shriver
Принадлежит: Massachusetts Institute of Technology

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Подробнее
Номер записи: 46
02-02-2012 дата публикации

Storage-stable aqueous ophthalmic formulations

Номер: US20120028910A1
Автор: Elisabeth Latour, Harun Takruri, Jean-Philippe Combal
Принадлежит: Fovea Pharmaceuticals SA

Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

Подробнее
Номер записи: 47
02-02-2012 дата публикации

Cosmetic compositions comprising oridonin and new cosmetic uses

Номер: US20120028916A1
Автор: Arnaud Fournial, Philippe Mondon
Принадлежит: Sederma SA

The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.

Подробнее
Номер записи: 48
02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1
Автор: Fotini Sampalis
Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее
Номер записи: 49
02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1
Автор: Christoph Hoenke, Dieter Wolfgang Hamprecht, Domnic Martyres, Peter Seither, Ralf Anderskewitz, Thorsten Oost, Wolfgang Rist
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее
Номер записи: 50
02-02-2012 дата публикации

Medicinal Cream Made Using Neomycin Sulphate, Betamethasone Valerate, And Chitosan, And A Process To Make The Same

Номер: US20120028942A1
Автор: Haridas Sankar, Kuppusamy Senthilkumar, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Vanangamudi Subramaniam Sulur
Принадлежит: Apex Labs Private Ltd

The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) a combination of active pharmaceutical ingredients (APIs), neomycin sulphate & betamethasone valerate used in treating bacterial skin infections & skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, a corticosteroid Betamethasone Valerate, and an antibacterial agent Neomycin Sulphate, are incorporated in cream base for use in treating bacterial skin infections and skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.

Подробнее
Номер записи: 51
02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1
Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
Номер записи: 52
02-02-2012 дата публикации

Compositions and methods for treating or preventing radiation injury

Номер: US20120029071A1
Автор: Rajesh K. Thimmulappa, Shyam Biswal
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.

Подробнее
Номер записи: 53
09-02-2012 дата публикации

Extracellular matrix compositions for tissue regeneration

Номер: US20120034191A1
Автор: Robert G. Matheny
Принадлежит: Individual

The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.

Подробнее
Номер записи: 54
09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1
Автор: Antonia Orsi, Daryl Rees, Patrick Howson, Yaer Hu, Zongqin Xia
Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее
Номер записи: 55
09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1
Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS
Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее
Номер записи: 56
09-02-2012 дата публикации

Compositions for the treatment of gluten intolerance and uses thereof

Номер: US20120034299A1
Автор: Hugh James Beatty Cornell, Teodor Stelmasiak
Принадлежит: Glutagen Pty Ltd

The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.

Подробнее
Номер записи: 57
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Автор: Brisdell Hunte, Hilary Clark, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, Sarah C. Bodary-Winter, Thomas D. Wu, William I. Wood
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
Номер записи: 58
09-02-2012 дата публикации

Combination of compounds for treating or preventing skin diseases

Номер: US20120035123A1
Автор: André Jomard, Laurent Fredon, Olivier Roye
Принадлежит: Galderma Research and Development SNC

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.

Подробнее
Номер записи: 59
09-02-2012 дата публикации

Substituted dihydropyrazolones and their use

Номер: US20120035151A1
Автор: Friederike Stoll, Hartmut Beck, Ingo Flamme, Mario Jeske, Metin Akbaba
Принадлежит: Bayer Pharma AG

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Подробнее
Номер записи: 60
09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1
Автор: Johan D. Oslob, Kenneth Barr, Min Zhong, Wang Shen
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее
Номер записи: 61
09-02-2012 дата публикации

Sphingo-guanidines and their use as inhibitors of sphingosine kinase

Номер: US20120035268A1
Автор: Alicja Bielawska, James Norris, Lina M. Obeld, LIU Xiang, Yusuf A. Hannun, Zdzislaw M. Szulc
Принадлежит: Medical University of South Carolina (MUSC)

The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting sphingosine kinase, and their use in the treatment and/or prevention of diseases and/or conditions associated with undesirable ceramidase or sphingosine kinase activity, including, but not limit cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, immunological disorders, asthma, atopic dermatitis, wound healing, and other proliferative diseases.

Подробнее
Номер записи: 62
09-02-2012 дата публикации

Methods for applying a skin graft

Номер: US20120035619A1
Автор: Andrew Ziegler, M. Josh Tolkoff, Sameer Ahmed Sabir
Принадлежит: Momelan Technologies Inc

The present invention generally relates to methods for applying a skin graft. Methods of the invention involve harvesting an epidermal skin graft, and applying the epidermal skin graft to a recipient site such that the basal layer of the skin graft makes direct contact with the recipient site.

Подробнее
Номер записи: 63
16-02-2012 дата публикации

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Номер: US20120039874A1
Автор: Katsunari Tezuka, Nobuaki Hori, Takashi Tsuji
Принадлежит: Japan Tobacco Inc

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Подробнее
Номер записи: 64
16-02-2012 дата публикации

Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Номер: US20120039980A1
Автор: David M. Gravett, George Y. Daniloff, Jacqueline Schroeder, Louis C. Sehl, Olof Mikael Trollsas, Philip M. Toleikis
Принадлежит: AngioDevice International GmbH

Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

Подробнее
Номер записи: 65
16-02-2012 дата публикации

Anti-dandruff compositions with citrus fibers

Номер: US20120040003A1
Автор: Albert Joseph Post, Georgia Shafer, Yury Yarovoy
Принадлежит: Conopco Inc

A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts.

Подробнее
Номер записи: 66
16-02-2012 дата публикации

Brimonidine compositions for treating erythema

Номер: US20120040016A1
Автор: Christopher V. Powala, Klaus P. Theobald
Принадлежит: Individual

The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient.

Подробнее
Номер записи: 67
16-02-2012 дата публикации

Collagen peptide composition having good ability to enter the blood and food or beverage containing the same

Номер: US20120040055A1
Автор: Hidetoshi Nishizawa, Hiroki Ohara, Hitoshi Matsumoto, Koichi Terauchi, Masataka Hata
Принадлежит: Meiji Co Ltd

An object of the present invention is to elucidate a collagen peptide effective for causing dipeptides or tripeptides serving as the active component to enter the blood, and thus to reduce the required intake thereof. According to the present invention, a collagen peptide composition obtained by digesting collagen or gelatin with protease is provided, wherein: (a) the ratio of hydroxyproline to total of amino acid residues at the second position from the N terminus of the peptides in the composition is 2 mol % or more and 20 mol % or less, and the ratio of glycine to total of amino acid residues at the third position from the N terminus of the peptides in the composition is 20 mol % or more and 50 mol % or less; and (b) the average molecular weight is 500 or more and 2000 or less.

Подробнее
Номер записи: 68
16-02-2012 дата публикации

Novel biomaterials, their preparation and use

Номер: US20120040901A1
Автор: Christian Schoch, György Lajos KIS, Jozsef Szejtli, Lajos Szente
Принадлежит: Individual

The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

Подробнее
Номер записи: 69
16-02-2012 дата публикации

Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof

Номер: US20120040984A1
Автор: Christophe Philippo, Claudie Namane, Eric Nicolai, Eykmar Fett, Patrick Mougenot
Принадлежит: SANOFI SA

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.

Подробнее
Номер записи: 70
16-02-2012 дата публикации

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Номер: US20120041031A1
Автор: Daniel W. Gil, John E. Donello, Lauren M.B. Luhrs, Veena Viswanath
Принадлежит: Allergan Inc

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.

Подробнее
Номер записи: 71
23-02-2012 дата публикации

Compositions comprising paulownin and/or paulownia extracts and uses thereof

Номер: US20120045407A1
Автор: Claude Saliou, Khalid Mahmood, Michael Southall, Simarna Kaur
Принадлежит: Individual

Provided are compositions comprising botanical extracts from certain species of the genus Paulownia , methods of lightening the skin therewith, and other uses thereof. Also provided are compositions comprising the compound paulownin, methods of lightening the skin therewith, and other uses thereof.

Подробнее
Номер записи: 72
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Автор: Alexey V. Teplyakov, Ellen Chi, Gopalan Raghunathan, Hong Mimi Zhou, Jill Giles-Komar, Jill M. Carton, Johan Fransson, Juan C. Almagro, Karyn T. O'neil, Linus Hyun, Ronald V. Swanson, Shanrong Zhao, Wendy Cordier, Yiqing Feng
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
Номер записи: 73
23-02-2012 дата публикации

Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Номер: US20120045455A1
Автор: Alan D. Robertson, Diego Silva, Ian Alexander McDonald
Принадлежит: PHARMAXIS LTD

Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosis after surgery, glaucoma, tendon scarring disorders, joint scarring disorders, kidney interstitial fibrosis and glomerular fibrosis and tubular fibrosis of the kidney.

Подробнее
Номер записи: 74
23-02-2012 дата публикации

TNF-alpha Antagonists Containing IGFBP5

Номер: US20120046217A1
Автор: Jae-ho Huh, Jae-Ryoung Hwang, Je-Ho Lee
Принадлежит: Sungkyunkwan University Foundation For Corporate Collaboration

The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Подробнее
Номер записи: 75
23-02-2012 дата публикации

STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY

Номер: US20120046253A1
Автор: Michael Fox, Rakefet Cohen
Принадлежит: Teva Pharmaceutical Industries LTD

Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of making such compositions, and methods for treating psoriasis using such compositions.

Подробнее
Номер записи: 76
23-02-2012 дата публикации

Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases

Номер: US20120046270A1
Автор: Andreas Mantoulidis, Peter Ettmayer, Steffen Steurer
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

Подробнее
Номер записи: 77
01-03-2012 дата публикации

Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Номер: US20120052097A1
Автор: Jungyeon Hwang, Oliver S. Fetzer, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson
Принадлежит: Cerulean Pharma Inc

Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles.

Подробнее
Номер записи: 78
01-03-2012 дата публикации

Novel use of compounds for treating and alleviating cellulite

Номер: US20120052141A1
Автор: Joseph Schwager, Karin Wertz, Regina Goralczyk
Принадлежит: DSM IP ASSETS BV

The present invention is directed inter alia to the use of at least one compound selected from the group consisting of (−)-epigallocatechin gallate, resveratrol, eicosapentaenoic acid, docosahexaenoic acid, rose hip extract/concentrate, hydroxytyrosol, lycopene, lutein, β-cryptoxanthin, zeaxanthin and derivatives thereof, for the treatment of cellulite, for the prevention of the development of mild cellulite, for the prevention of the progression of mild cellulite to severe cellulite, for smoothening the micro relief of the skin, for maintaining or increasing the tensile properties of the skin, and/or for reducing the fat mass and the circumference at the hips and thighs, as well as to the corresponding cosmetic and medical methods.

Подробнее
Номер записи: 79
01-03-2012 дата публикации

(R)-(-)-1,2-propanediol compositions and methods

Номер: US20120053152A1
Автор: Edward T. Wei
Принадлежит: Individual

Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agent's cooling activity from inhibition when in the presence of a short-chain alcohol.

Подробнее
Номер записи: 80
01-03-2012 дата публикации

Splice-region antisense composition and method

Номер: US20120053228A1
Автор: Patrick L. Iversen, Robert Hudziak
Принадлежит: AVI Biopharma Inc

Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. Such targeting is effective to inhibit natural mRNA splice processing, produce splice variant mRNAs, and inhibit normal expression of the protein.

Подробнее
Номер записи: 81
01-03-2012 дата публикации

Alkylamido Compounds and Uses Thereof

Номер: US20120053244A1
Автор: Francesca Viti, Salvatore Bellinvia, Sergio Baroni
Принадлежит: Individual

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Подробнее
Номер записи: 82
01-03-2012 дата публикации

Methods of Treating Hair Related Conditions

Номер: US20120053245A1
Автор: Francesca Viti, Salvatore Bellinvia, Sergio Baroni
Принадлежит: Individual

Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.

Подробнее
Номер записи: 83
08-03-2012 дата публикации

Treatment of cutaneous hemangioma

Номер: US20120058056A1
Автор: Suqin Guo
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.

Подробнее
Номер записи: 84
08-03-2012 дата публикации

Two component interactive emulsion product

Номер: US20120058062A1
Автор: John C. Carson
Принадлежит: Carson Product Development Inc

The present invention describes, in one aspect, the use of two oppositely charged surfactants as the primary emulsifiers in two separated parts of a product. The emulsifiers are chosen such that when the two parts of the emulsion product are mixed, the emulsifiers react to form water insoluble compounds that are no longer able to function as emulsifiers, thus, the oil phase of the emulsion is precipitated onto the skin along with the emulsifier reaction product. Since none of the deposited materials are water soluble, or capable of functioning as emulsifiers, the deposited oil phase is extremely resistant to being washed off. This technology finds applications in hand and body creams and lotions, baby care products, sunscreens, skin protective products, makeup systems, and automotive and furniture polishes.

Подробнее
Номер записи: 85
08-03-2012 дата публикации

Process for treating and/or forming a non-newtonian fluid using microchannel process technology

Номер: US20120058063A1
Автор: Anna Lee Tonkovich, David Kilanowski, Eric Daymo, Ravi Arora
Принадлежит: Individual

The disclosed invention relates to a process, comprising: conducting unit operations in at least two process zones in a process microchannel to treat and/or form a non-Newtonian fluid, a different unit operation being conducted in each process zone; and applying an effective amount of shear stress to the non-Newtonian fluid to reduce the viscosity of the non-Newtonian fluid in each process zone, the average shear rate in one process zone differing from the average shear rate in another process zone by a factor of at least about 1.2.

Подробнее
Номер записи: 86
08-03-2012 дата публикации

Anti- integrin antibodies, compositions, methods and uses

Номер: US20120058128A1
Автор: Jill Giles-Komar, Linda Snyder, Marian T. Nakada, Mohit Trikha
Принадлежит: Janssen Biotech Inc

The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Подробнее
Номер записи: 87
08-03-2012 дата публикации

Activated leukocyte composition and uses for wound healing

Номер: US20120058156A1
Автор: Adi Zuloff-Shani, Eilat Bain, Eilat Shinar, Irene Ginis, Marina Bubis, Mitchell Shirvan, Orit Frenkel
Принадлежит: Macrocure Ltd

Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.

Подробнее
Номер записи: 88
08-03-2012 дата публикации

Cleaning or cosmetic compositions comprising natural zeolites

Номер: US20120058164A1
Автор: Paul Lap Shun Chan, Philip John Ashenden, Ray John Merchant
Принадлежит: ZEOSOFT Ltd

The invention describes compositions which are useful as cleansers of the skin. The compositions described comprise zeolitic ingredients which are in general softer than known products. The natural zeolitic ingredients are inherently soft. The softness is due to a number of factors including but not limited to younger zeolitic rock types, softer constituent elements, more porous rock types and less dense rock types. The overall softness provided by the compositions according to the invention provides a cleaning product that is softer to the skin, especially the human skin.

Подробнее
Номер записи: 89
08-03-2012 дата публикации

Therapeutic or prophylactic agent for dyskinesia

Номер: US20120058186A1
Автор: Kotoe Ohta, Suguru Takaki, Yasuhide Horiuch
Принадлежит: TORAY INDUSTRIES INC

The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.

Подробнее
Номер записи: 90
08-03-2012 дата публикации

Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin

Номер: US20120058199A1
Автор: Andreas Buthe, Andreas Hafner, Babette Fiedler, Franz Kaufmann, Gordon Bradley, Guido Meurer
Принадлежит: BASF SE

The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.

Подробнее
Номер записи: 91
08-03-2012 дата публикации

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Номер: US20120058945A1
Автор: Abraham Warshawsky, Hailin Zheng, Matitiyahu Fridkin, Moussa Youdim, Rivka Warshawsky
Принадлежит: Technion Research and Development Foundation Ltd, Yeda Research and Development Co Ltd

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.

Подробнее
Номер записи: 92
08-03-2012 дата публикации

Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same

Номер: US20120058952A1
Автор: Claude Dal Farra, Jean-Marie Botto, Nouha Domloge
Принадлежит: ISP Investments LLC

The present invention relates to a peptide of general formula (I): R 1 -(AA) n -X 1 -Gly-Glu-Leu-Ser-X 2 -X 3- (AA) p -R 2 , derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Подробнее
Номер записи: 93
08-03-2012 дата публикации

Macrolides with Anti-Inflammatory Activity

Номер: US20120058963A1
Автор: Antun Hutinec, Dubravko Jelic, Goran Kragol, Marija Ribic, Martina Bosnar, Nikola Marjanovic, Ognjen Culic, Sulejman Alihodzic, Vanja Vela, Vesna Erakovic Haber, Zorica Marusic-Istuk
Принадлежит: Glaxo Group Ltd

The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.

Подробнее
Номер записи: 94
08-03-2012 дата публикации

Di-azetidinyl diamide as monoacylglycerol lipase inhibitors

Номер: US20120058986A1
Автор: Bin Zhu, Mark J. Macielag, Peter J. Connolly
Принадлежит: Janssen Pharmaceutica NV

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

Подробнее
Номер записи: 95
08-03-2012 дата публикации

Novel kinase modulators

Номер: US20120059001A1
Автор: Govindarajulu Babu, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Swaroop Kumar V.S. Vakkalanka
Принадлежит: Incozen Therapeutics Pvt Ltd, Rhizen Pharmaceuticals SA

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Подробнее
Номер записи: 96
08-03-2012 дата публикации

Inhibition of map4k4 through rnai

Номер: US20120059046A1
Автор: Anastasia Khvorova, Joanne Kamens, Tod M Woolf, William Salomon
Принадлежит: RXi Pharmaceuticals Corp

RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.

Подробнее
Номер записи: 97
08-03-2012 дата публикации

Methods and compositions for modification of a hla locus

Номер: US20120060230A1
Автор: Andreas Reik, Edward J. Rebar, Fyodor Urnov, Jeffrey C. Miller, Laurence J.N. Cooper, Michael C. Holmes, Philip D. Gregory, Trevor Collingwood
Принадлежит: Individual

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Подробнее
Номер записи: 98
15-03-2012 дата публикации

Delivery system with scaffolds

Номер: US20120063997A1
Автор: Cheryl Hunter, Kevin Morris Shakessheff, Robin Andrew Quirk
Принадлежит: REGENTEC Ltd

An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance.

Подробнее
Номер записи: 99
15-03-2012 дата публикации

Method for Treating Psoriatic Arthritis by Administering an Anti-IL-12 Antibody

Номер: US20120063998A1
Автор: Bemard Scallon, David M. Knight, David Peritt, David Shealy, Jill Giles-Komar
Принадлежит: Individual

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.

Подробнее
Номер записи: 100